10-Q: Stimcell Energetics Inc. Reports Increased Operating Expenses and Net Loss in Q2 2025

Stimcell Energetics Inc. reports a significant increase in operating expenses and net loss for the second quarter of fiscal year 2025, alongside a reverse stock split and name change.

Summary

• Stimcell Energetics Inc., formerly Cell MedX Corp., reported its financial results for the quarter ended November 30, 2024.
• The company experienced a net loss of $139,508 for the three-month period and $206,427 for the six-month period.
• Operating expenses increased significantly, primarily due to a large foreign exchange loss and increased management and consulting fees.
• The company's cash balance was $33,821 as of November 30, 2024, with a working capital deficit of $982,705.
• The company funded its operations with $30,000 borrowed from a related party.
• A 1-for-15 reverse stock split was completed on November 1, 2024, reducing the outstanding shares to 19,816,272.
• The company also changed its name from Cell MedX Corp. to Stimcell Energetics Inc.
• The company has a going concern warning due to accumulated losses and the need for additional financing.

Sentiment

Score: 2

Explanation: The document indicates a very negative outlook due to significant losses, a going concern warning, and ineffective internal controls. The company's reliance on related party loans and lack of revenue generation further contribute to the low sentiment.

Positives

• The company recorded a gain of $1,569 on forgiveness of debt due to balances exceeding the statute of limitations.
• The company secured $30,000 in financing through a related party loan.

Negatives

• The company's net loss increased significantly in both the three and six-month periods.
• Operating expenses increased substantially, driven by foreign exchange losses and higher management and consulting fees.
• The company has a significant working capital deficit of $982,705.
• The company has a going concern warning due to accumulated losses and the need for additional financing.
• The company has not generated any revenue during the reported periods.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of segregation of duties.

Risks

• The company operates in a highly competitive market with well-established competitors.
• The company is subject to numerous governmental regulations, which can increase costs and delay product development.
• The company's intellectual property rights may not be adequately protected or enforced.
• The company's research and development efforts may not result in commercially successful products.
• The company may face safety concerns with its products, which could negatively impact sales.
• The company may not be able to attract and maintain key personnel.
• The company has a limited operating history and has generated minimal revenues.
• The company needs to acquire additional financing, or its business will fail.
• The company expects to raise additional capital through the offering of more shares, which will result in dilution to its current shareholders.
• The company may convert some of its existing debt into shares of its common stock, which will result in dilution to its current shareholders.
• The company may consolidate its issued and outstanding shares of common stock, which may negatively impact the share price.
• There is a limited market for the company's common stock, which may restrict shareholders' ability to resell their shares.
• The company's stock is a penny stock, which limits stockholders' ability to sell their stock.
• The company has not paid nor anticipates paying cash dividends on its common stock.

Future Outlook

The company's future is uncertain, with a going concern warning due to accumulated losses and the need for additional financing. Management intends to obtain additional funding through borrowing from directors and officers, issuing promissory notes, and/or private placement of common stock.

Management Comments

• Management believes all adjustments necessary for a fair presentation of the results of operations and financial position have been included.
• Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
• Management concluded that the disclosure controls and procedures were not effective due to lack of segregation of duties.

Industry Context

The company operates in the competitive biotech industry, facing challenges from larger, well-established medical device and pharmaceutical companies. The market for diabetes and pain management is subject to rapid change and new product introductions, requiring continuous innovation and adaptation.

Comparison to Industry Standards

• The company's lack of revenue and significant losses are not uncommon for early-stage biotech companies, but the magnitude of the losses and the going concern warning are concerning.
• Compared to established medical device companies like Bayer Corp., Becton Dickinson Corp., and Johnson & Johnson, Stimcell Energetics is significantly smaller and has limited resources.
• The company's reliance on related party loans is a common practice for early-stage companies but also indicates a higher risk profile.
• The company's research and development efforts are currently on hold due to financial difficulties, which is a significant deviation from industry standards for companies in the biotech sector.

Related Party Transactions

• The company has significant transactions with related parties, including loans, management fees, and consulting fees.
• Amounts due to related parties totaled $325,945 as of November 30, 2024.
• Notes and advances due to related parties totaled $366,484 as of November 30, 2024.
• The company borrowed $30,000 from a related party in exchange for a 10% note payable due on demand.
• An entity controlled by a director and a significant shareholder agreed to forgive a total of $3,165 the company owed for royalties.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution.
• Employees may be impacted by the company's financial difficulties and potential restructuring.
• Customers may be affected by delays in product development and potential discontinuation of services.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to address the deficiencies in its disclosure controls and procedures.
• The company needs to develop a plan to generate revenue and achieve profitability.

Key Dates

Keywords

biotech, microcurrents, eBalance Technology, reverse stock split, operating expenses, net loss, related party transactions, going concern, financial statements, debt financing